BREASTRecruiting

Repeat radiation therapy to the breast using proton therapy following a recurrence of breast cancer

Gender
Women
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase

What is this trial about?

For breast cancer, breast-conserving surgery followed by radiation therapy to the entire breast is a proven standard of care; however, in some cases, a recurrence may occur in the breast that has already been treated with radiation. In this case, a complete removal of the breast (mastectomy) is the treatment of choice. The goal of the BREAST study is to investigate whether repeated, targeted partial breast irradiation with proton therapy following a repeat breast-conserving surgery is a safe and well-tolerated treatment option. Women aged 18 and older with recurrent or newly diagnosed breast cancer in the previously irradiated breast who have undergone a repeat breast-conserving surgery are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: breast cancer

Age: 18 years and older

Line of therapy: Unabhängig von Therapielinie

Key inclusion criteria: women; recurrent or new tumour in the breast that has already been treated with radiotherapy; following a repeat breast-conserving operation; new tumour smaller than 3 cm; no lymph nodes affected; tumour-free margins at the time of surgery (R0 resection); last radiotherapy session at least twelve months ago

Allocation

Einarmige Studie

Treatment

breast irradiation using proton therapytreatment lasting over 15 sessions

Follow-up

60 months

Detailed description

Breast cancer is the most common cancer among women. After breast-conserving surgery, the entire breast is typically treated with radiation to reduce the risk of recurrence. Nevertheless, some patients may experience a recurrence of the tumor in the same breast. Until now, a mastectomy (complete removal of the breast) has often been recommended in such cases, as repeat radiation therapy using conventional methods carries an increased risk of side effects on the skin and surrounding tissue that have already been irradiated. Proton therapy is a novel radiation treatment method with unique physical properties. The protons (positively charged particles) deliver their energy specifically to the tumor area (known as the Bragg peak), thereby better sparing the surrounding healthy tissue than conventional radiation therapy using photons. Proton therapy is already used as a radiation treatment for various types of cancer; however, in Germany, it has not yet been established as a treatment for repeat partial breast irradiation in cases of breast cancer recurrence.

The aim of this study is to investigate the efficacy and tolerability of partial breast irradiation with proton therapy following a repeat breast-conserving surgery. The treatment consists of 15 individual sessions. This is a single-arm study, meaning all patients receive the same treatment. The primary endpoint of the study is the occurrence of severe skin reactions (grade 3 or higher) within the first six months after the start of partial breast irradiation.

Women aged 18 and older with recurrent or newly diagnosed breast cancer in a breast that has already been treated with radiation, who have undergone a repeat breast-conserving surgery, are eligible to participate in this study. Additional eligibility criteria include, among others, that the recurrent tumor is smaller than 3 cm, no lymph nodes are involved, the tumor margins were tumor-free at the time of surgery (R0 resection), and at least twelve months have passed since the last radiation treatment.

Facts

  1. Disease: Breast cancer (mammary carcinoma)
  2. Cancer characteristics: Recurrent (reappeared) or newly developed in a breast that has already undergone radiation therapy, following repeat breast-conserving surgery
  3. What the study investigates: The efficacy and tolerability of repeat partial breast irradiation with proton therapy following a repeat breast-conserving surgery
  4. Study objective: To determine whether proton therapy can be used as an alternative treatment following a repeat breast-conserving surgery and to assess the frequency of severe skin reactions
  5. Study duration: up to approximately 6 months + up to 5 years of follow-up
  6. Study characteristics: single-arm, open-label

Trial sites

2 trial sites in Germany are listed.

  • Nationales Centrum für Tumorerkrankungen Heidelberg

    Im Neuenheimer Feld 280, 69120 Heidelberg

    Recruiting
  • University Hospital Heidelberg, Department Radiation Oncology

    69120 Heidelberg

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT06954623) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.